COMMUNIQUÉS West-GlobeNewswire

Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments
30/10/2025
Tori Spelling shares her and her family’s journey with eczema and seborrheic dermatitis to encourage others to take control of their skin health ZORYVE® (roflumilast) is the #1 prescribed branded topical therapy for [...]
Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits
30/10/2025
Selects Greenstone Biosciences to Accelerate AI-Driven iPSC Precision Medicine Platform PHOENIX, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “ [...]
Kaida BioPharma Selected to Present at Two Upcoming Conferences
30/10/2025
Premier presenter semi-finalist for BIOPITCH at the Florida Innovation Conference Startup finalist for Tampa Tank Pitch Competition at the Disrupt the Bay Conference featuring Keynote Speaker, Cathie Wood from Ark [...]
Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development
30/10/2025
ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant [...]
Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development
30/10/2025
ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant [...]
Alethio Therapeutics Launches with New CEO and Chair to Advance Two Targeted Medicines for Myeloproliferative Neoplasms (Chronic Blood Cancers)
30/10/2025
Leveraging deep scientific and clinical expertise in MPNs to drive a pipeline of disease-modifying precision therapies that selectively target disease-driving cells Advancing AT-01, a first-in-class ADC programme, with [...]
Novo Nordisk submits proposal to acquire Metsera, Inc.
30/10/2025
Bagsværd, Denmark, 30 October 2025 – Novo Nordisk confirms that it submitted an unsolicited proposal to acquire Metsera, Inc. (Metsera). The acquisition of Metsera, including its early and development-stage incretin and [...]
Amneal Reports Third Quarter 2025 Financial Results
30/10/2025
‒ Q3 2025 Net Revenue of $785 million ; GAAP Net Income of $2 million ; Diluted Income per Share of $0.01 ‒ ‒ Adjusted EBITDA of $160 million ; Adjusted Diluted EPS of $0.17 ‒ ‒ Updated 2025 Full Year Guidance ‒ [...]
Sapu Nano to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus)
30/10/2025
AGOURA HILLS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat cancer [...]
Integra LifeSciences Reports Third Quarter 2025 Financial Results
30/10/2025
PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third quarter ending [...]
TOLREMO therapeutics Welcomes Multiple Myeloma Leader Kenneth C. Anderson to its Scientific Advisory Board
30/10/2025
Basel, October 30, 2025 – TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Kenneth C. Anderson, MD, a globally recognized leader in multiple myeloma research, to the company’s Scientific Advisory [...]
Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting
30/10/2025
Speaker panel will include collaborative case study presentations from strategic partners: Memorial Sloan Kettering Cancer Center, Bio-Rad Laboratories, and Thermo Fisher Scientific LOUISVILLE, Colo., Oct. 30, 2025 ( [...]
Agios Reports Third Quarter 2025 Financial Results and Provides Business Update
30/10/2025
$12.9 million in third quarter PYRUKYND ® (mitapivat) net revenues PDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025 CHMP adopted positive opinion for PYRUKYND in thalassemia; EC decision [...]
Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan
30/10/2025
WOODCLIFF LAKE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its Board of Directors (the “Board”) has adopted an amendment (the “ [...]
Cambridge Atomworks is delighted to announce the appointment of Mr Alistair Pettey as a non-executive director
30/10/2025
CAMBRIDGE, United Kingdom, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Alistair will lead on the growth and capital strategy for Cambridge Atomworks. Alistair has a passion for investing in companies that have a strong focus in [...]
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025
30/10/2025
CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on [...]
Tilray Brands Sets Sights on Asia: Bringing Award-Winning Craft Beers to Japan’s Premier American Craft Beer Experience Festival
30/10/2025
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, is [...]
Forward Therapeutics Announces First Participants Dosed in Phase 1 Healthy Volunteer Study of FT2109, a Next-Generation TNF Signaling Inhibitor
30/10/2025
PALM BEACH GARDENS, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Forward Therapeutics, Inc (“Forward”), a biotechnology company developing oral small molecule therapies for inflammation-driven diseases, today announced that [...]
QUVIVIQ sales up >130% driving Idorsia toward profitability – 9M 2025 results
30/10/2025
Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ (daridorexant) global net sales (excluding sales to partners) increased by >130% year-on-year to CHF 91 million in 9M 2025 – continuing Idorsia’s trajectory towards [...]

Pages